» Articles » PMID: 24579049

Oral Postdialysis Cholecalciferol Supplementation in Patients on Maintenance Hemodialysis: a Dose-response Approach

Overview
Journal Int J Nephrol
Publisher Wiley
Specialty Nephrology
Date 2014 Mar 1
PMID 24579049
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present study was to evaluate the dose of postdialysis cholecalciferol needed to maintain the 25-hydroxyvitamin D [25(OH)D] levels in the optimal range of 75-150 nmol/L. Twenty-six patients who had low baseline 25(OH)D levels (mean 27.5 ± 14.9 nmol/L) were studied. The 25(OH)D levels were measured every 2 months for one year. During the first two months, all the patients received 2000 IU of cholecalciferol after each hemodialysis (=6000 IU/wk). Thereafter, the dose was individualized and adapted every 2 months by administering 1 to 6 cholecalciferol tablets (2000 IU each) per week (total weekly dose = 2000-12000 IU/wk). During cholecalciferol supplementation, the 25(OH)D concentrations rapidly increased from baseline to 140.1 ± 28.3 nmol/L at month 6 and 95.6 ± 20.9 nmol/L at month 12. At month twelve, 86% of the patients had 25(OH)D levels within the target range with a mean dose of 5917 ± 4106 IU/wk of cholecalciferol; however, the amount needed to maintain these levels varied widely from 0 (n = 2) to 12000 IU/wk (n = 5). In conclusion, postdialysis cholecalciferol prescription is quite effective in correcting vitamin D deficiency/insufficiency, but the amount of cholecalciferol needed to maintain the 25(OH)D levels within the optimal range over the long-term varies widely among patients and must be individualized.

Citing Articles

The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients.

Tarasewicz A, Komorniczak M, Zakrzewska A, Biedunkiewicz B, Malgorzewicz S, Jankowska M Biomedicines. 2024; 12(2).

PMID: 38397979 PMC: 10886943. DOI: 10.3390/biomedicines12020377.


Effects of sun exposure and dietary vitamin D intake on serum 25-hydroxyvitamin D status in hemodialysis patients.

Lee Y, Oh I, Baek H, Lee C, Lee S Nutr Res Pract. 2015; 9(2):158-64.

PMID: 25861422 PMC: 4388947. DOI: 10.4162/nrp.2015.9.2.158.


Long-term cholecalciferol administration in hemodialysis patients: a single-center randomized pilot study.

Mieczkowski M, Zebrowski P, Wojtaszek E, Stompor T, Przedlacki J, Bartoszewicz Z Med Sci Monit. 2014; 20:2228-34.

PMID: 25382402 PMC: 4238795. DOI: 10.12659/MSM.892315.

References
1.
Jakopin E, Pecovnik Balon B, Ekart R, Gorenjak M . High-dose cholecalciferol supplementation for vitamin D deficiency in haemodialysis patients. J Int Med Res. 2011; 39(3):1099-106. DOI: 10.1177/147323001103900345. View

2.
Elder G . Vitamin D levels, bone turnover and bone mineral density show seasonal variation in patients with chronic kidney disease stage 5. Nephrology (Carlton). 2007; 12(1):90-4. DOI: 10.1111/j.1440-1797.2006.00754.x. View

3.
Verstuyf A, Carmeliet G, Bouillon R, Mathieu C . Vitamin D: a pleiotropic hormone. Kidney Int. 2010; 78(2):140-5. DOI: 10.1038/ki.2010.17. View

4.
Cuppari L, Carvalho A, Draibe S . Vitamin D status of chronic kidney disease patients living in a sunny country. J Ren Nutr. 2008; 18(5):408-14. DOI: 10.1053/j.jrn.2008.05.004. View

5.
Holick M . Evidence-based D-bate on health benefits of vitamin D revisited. Dermatoendocrinol. 2012; 4(2):183-90. PMC: 3427198. DOI: 10.4161/derm.20015. View